The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Lamotrigine for treatment of pain associated with diabetic neuropathy: Results of two randomized, double-blind, placebo-controlled studies
Abstract
To assess the efficacy and tolerability of lamotrigine in pain associated with diabetic neuropathy, two replicate randomized, double-blind, placebo-controlled studies were conducted. Patients (n=360 per study) with painful diabetic neuropathy were randomized to receive lamotrigine 200, 300, or 400 mg daily or placebo during the 19-week treatment phase, including a 7-week dose-escalation phase and a 12-week, fixed-dose maintenance phase. The mean reduction in pain-intensity score from baseline to week 19 (primary endpoint) was greater (p < or = 0.05) in patients receiving lamotrigine 400 mg than placebo in Study 2 (observed scores, -2.7 versus -1.6 on a 0- to 10-point scale). This finding was not replicated in Study 1. Lamotrigine 200 and 300 mg did not significantly differ from placebo at week 19 in either study. Lamotrigine 300 and 400 mg were only occasionally more effective than placebo for secondary efficacy endpoints. The 200-mg dose did not separate from placebo. In a post hoc analysis of pooled data including only patients who reached their target dose, lamotrigine 400 mg conferred greater (p0.05) mean reduction in pain-intensity score from baseline to week 19 than placebo (-2.5 for 300 mg and -2.7 for 400mg versus -2.0 for placebo). Adverse events were reported in 71-82% of lamotrigine-treated patients compared with 63-70% of placebo-treated patients. The most common adverse events with lamotrigine were headache and rash. Compared with placebo, lamotrigine (300 and 400 mg daily) was inconsistently effective for pain associated with diabetic neuropathy but was generally safe and well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pirart, J. (1978) · Diabetes Care · doi:10.2337/diacare.1.3.168 · Cited by 1,290
Diabetic Neuropathy: An intensive review
Duby, J. J., Campbell, R. K., Setter, S. M., White, J. R., & Rasmussen, K. A. (2004) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/61.2.160 · Cited by 382
Self-citationSafety Review of Adult Clinical Trial Experience with Lamotrigine
Messenheimer, J., Mullens, E. L., Giorgi, L., & Young, F. (1998) · Drug Safety · doi:10.2165/00002018-199818040-00004 · Cited by 252 · cited 3×
“…incidence of rash (non-serious and serious) in these studies was comparable to or lower than that observed in epilepsy and bipolar-disorder studies (Messenheimer et al., 1998; Bowden et al., 2004); however, the sample size of the current study was too small to assess accurately the potential for…”
Result
Cited by
Pharmacologic management of neuropathic pain: Evidence-based recommendations
Dworkin, R. H., O’Connor, A. B., Backonja, M., Farrar, J. T., Finnerup, N. B., Jensen, T. S., Kalso, E. A., Loeser, J. D., Miaskowski, C., Nurmikko, T. J., et al. (2007) · Pain · doi:10.1016/j.pain.2007.08.033 · Cited by 2,126
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision
Attal, N., Cruccu, G., Baron, R., Haanpää, M., Hansson, P., Jensen, T. S., & Nurmikko, T. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.02999.x · Cited by 1,873
Dworkin, R. H., O'Connor, A. B., Audette, J., Baron, R., Gourlay, G. K., Haanpää, M. L., Kent, J. L., Krane, E. J., LeBel, A. A., Levy, R. M., et al. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0649 · Cited by 1,325
Diabetic neuropathy: clinical manifestations and current treatments
Callaghan, B. C., Cheng, H. T., Stables, C. L., Smith, A. L., & Feldman, E. L. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70065-0 · Cited by 1,211
The evidence for pharmacological treatment of neuropathic pain
Finnerup, N. B., Sindrup, S. H., & Jensen, T. S. (2010) · Pain · doi:10.1016/j.pain.2010.06.019 · Cited by 1,045
Diabetic neuropathy: Mechanisms to management
Edwards, J. L., Vincent, A. M., Cheng, H. T., & Feldman, E. L. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.05.005 · Cited by 790
Bril, V., England, J., Franklin, G. M., Backonja, M., Cohen, J., Del Toro, D., Feldman, E., Iverson, D. J., Perkins, B., Russell, J. W., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182166ebe · Cited by 634
Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy
Iqbal, Z., Azmi, S., Yadav, R., Ferdousi, M., Kumar, M., Cuthbertson, D. J., Lim, J., Malik, R. A., & Alam, U. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.04.001 · Cited by 487
Demant, D. T., Lund, K., Vollert, J., Maier, C., Segerdahl, M., Finnerup, N. B., Jensen, T. S., & Sindrup, S. H. (2014) · Pain · doi:10.1016/j.pain.2014.08.014 · Cited by 440
Diabetic peripheral neuropathy: Current perspective and future directions
Singh, R., Kishore, L., & Kaur, N. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.12.005 · Cited by 400
Dworkin, R. H., Turk, D. C., Peirce-Sandner, S., Baron, R., Bellamy, N., Burke, L. B., Chappell, A., Chartier, K., Cleeland, C. S., Costello, A., et al. (2010) · Pain · doi:10.1016/j.pain.2010.02.018 · Cited by 381
Self-citationPainful Diabetic Neuropathy: Epidemiology, Natural History, Early Diagnosis, and Treatment Options
Veves, A., Backonja, M., & Malik, R. A. (2008) · Pain Medicine · doi:10.1111/j.1526-4637.2007.00347.x · Cited by 375
Freeman, R., Durso-DeCruz, E., & Emir, B. (2008) · Diabetes Care · doi:10.2337/dc07-2105 · Cited by 322
Baron, R., Tölle, T. R., Gockel, U., Brosz, M., & Freynhagen, R. (2009) · Pain · doi:10.1016/j.pain.2009.06.001 · Cited by 316
Neuropathic pain: Are there distinct subtypes depending on the aetiology or anatomical lesion?
Attal, N., Fermanian, C., Fermanian, J., Lanteri-Minet, M., Alchaar, H., & Bouhassira, D. (2008) · Pain · doi:10.1016/j.pain.2008.01.006 · Cited by 309
Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets
Dewanjee, S., Das, S., Das, A. K., Bhattacharjee, N., Dihingia, A., Dua, T. K., Kalita, J., & Manna, P. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.06.034 · Cited by 300
Schmalhofer, W. A., Calhoun, J., Burrows, R., Bailey, T., Kohler, M. G., Weinglass, A. B., Kaczorowski, G. J., Garcia, M. L., Koltzenburg, M., & Priest, B. T. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.047670 · Cited by 301
Diabetic Painful and Insensate Neuropathy: Pathogenesis and Potential Treatments
Obrosova, I. G. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.07.004 · Cited by 272
Treating pain in diabetic neuropathy: current and developmental drugs
Alam, U., Sloan, G., & Tesfaye, S. (2020) · Drugs · doi:10.1007/s40265-020-01259-2 · Cited by 104
Cepeda, M. S., Berlin, J. A., Gao, C. Y., Wiegand, F., & Wada, D. R. (2012) · Pain Medicine · doi:10.1111/j.1526-4637.2012.01340.x · Cited by 71
Huffman, C., Stacey, B. R., Tuchman, M., Burbridge, C., Li, C., Parsons, B., Pauer, L., Scavone, J. M., Behar, R., & Yurkewicz, L. (2015) · The Clinical Journal of Pain · doi:10.1097/ajp.0000000000000198 · Cited by 37
Self-citation
Metadata
- Authors
- Vinik, A. I., Tuchman, M., Safirstein, B., Corder, C., Kirby, L., Wilks, K., Quessy, S., Blum, D., Grainger, J., White, J., & Silver, M.
- Venue
- Pain
- Published
- 2007-03
- Volume
- 128
- Issue
- 1
- Pages
- 169-179
- ISSN
- 0304-3959 (ISSN-L)
- OpenAlex
- W2034884858
- Cited by
- 163
- References
- 3
- FWCI
- 11.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.